SWOG clinical trial number
CTSU/E1412

Randomized Phase II Open Label Study of Lenalidomide R-CHOP (R2CHOP) vs. RCHOP (Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone) in Patients with Newly Diagnosed Diffuse Large B Cell Lymphoma

Closed
Phase
Abbreviated Title
R2CHOP vs. RCHOP in newly diagnosed DLBCL
Status Notes
This study is permanently closed to Step 0 accrual effective January 17, 2017 at 5:00pm ET.
Activated
06/01/2014
Closed
01/17/2017
Participants
CTSU

Research committees

Lymphoma

Treatment

Cyclophosphamide Prednisone Vincristine Doxorubicin Rituximab CC-5013 (Lenalidomide)

Publication Information Expand/Collapse

2022

Development of a Conditional Event-Free Survival Tool in Diffuse Large B-Cell Lymphoma

D Luan;Z Chen;L Jakobsen;M Maurer;T El-Galaly;L Nastoupil;J Cerhan;C Flowers;B Link;I Lossos;D Stephens;T Habermann;G Nowakowski;N Bartlett;J Friedberg;B Kahl;J Leonard;K Smedby;M Jerkeman;P Martin ASH Annual Meeting (Dec 10 thru 13, 2022, New Orleans, LA), oral

2021

Addition of Lenalidomide to R-CHOP Improves Outcomes in Newly Diagnosed Diffuse Large B-Cell Lymphoma in a Randomized Phase II US Intergroup Study ECOG-ACRIN E1412

G Nowakowski;F Hong;D Scott;W Macon;R King;T Habermann;M Wagner-Johnston;C Casulo;JL Wade, III;G Nagargoje;C Reynolds;J Cohen;N Khan;J Amengual;K Richards;R Little;J Leonard;JW Friedberg;L Kostakoglu;B Kahl;T Witzig Journal of Clinical Oncology Apr 20;39(12):1329-1338. doi: 10.1200/JCO.20.01375. Epub 2021 Feb 8.

PMid: PMID33555941 | PMC number: PMC8078264

2019

Factors That Potentially Impact Lenalidomide/R-CHOP (R2-CHOP) Efficacy in Previously Untreated Diffuse Large B-Cell Lymphoma in the ROBUST and ECOG-ACRIN 1412 Studies

G Nowakowski;A Chiappella;F Hong;R Gascoyne;DW Scott;W Macon;RL King;JE Amengual;RF Little;JP Leonard;JW Friedberg;L Kostakoglu;W Jurczak;K Yamamoto;M Czuczman;J Russo;K Hudak;J Zhang;S Wade;T Witzig;BS Kahl;U Vitolo Blood (2019) 134 (Supplement_1): 4092, abst 626; American Society of Hematology Annual Meeting (Dec 7-10, 2019, Orlando, FL), poster

Other Clinical Trials

SWOG Clinical Trial Number
S2207

Randomized Phase II Study of the Addition of Targeted Therapeutic Agents to Tafasitamab-Based Therapy in Non-Transplant-Eligible Patients with Relapse/Refractory Large B-Cell Lymphoma
Research Committee(s)
Lymphoma
Activated
06/30/2023
Accrual
5%
Open
Phase
SWOG Clinical Trial Number
CTSU/AHOD2131

A Randomized Phase 3 Interim Response Adapted Trial Comparing Standard Therapy with Immuno-oncology Therapy for Children and Adults with Newly Diagnosed Stage I and II Classic Hodgkin Lymphoma
Research Committee(s)
Lymphoma
Immunomolecular Therapeutics
Activated
04/28/2023
Open
Phase
SWOG Clinical Trial Number
S2114

A Randomized Phase II trial of consolidation therapy following CD19 CAR T-cell treatment for Relapsed/Refractory Diffuse Large B-cell Lymphoma or Grade IIIB Follicular Lymphoma
Research Committee(s)
Lymphoma
Activated
02/23/2023
Accrual
10%
Open
Phase